Thinking of stopping because of the cost
Published research tracking 73,895 new GLP-1 users found roughly 1 in 4 stop within the first year, and cost is one of the independent factors. Here is the uncomfortable part: many people quit while paying a price that had a cheaper legitimate door right next to it. Three checks, free, before you decide anything.
If your monthly cost is over $500, there is a real chance you are on the most expensive door. Manufacturer-direct pricing, no insurance needed, as of our last Monday audit:
| Option | Real monthly, maintenance dose | The door people overpay at |
|---|---|---|
| Wegovy pen, NovoCare direct | $349 flat | $1,229-1,419 couponed at the counter |
| Zepbound, LillyDirect direct | $449 (45-day refill rule) | $599-1,049 if the window lapses |
| Oral options, maintenance doses | $199-299 | $149 headlines are starter doses only |
Two quiet mechanisms push a manageable bill into quitting territory: a missed 45-day refill window on LillyDirect resets $449 to $599-1,049 depending on dose, and some programs bill in 12-week lumps, so a "$199 a month" plan hits your card as roughly $597 at once. Both look like "the price went up." Both are often reversible or avoidable.
Coverage and savings-card terms changed repeatedly in 2026, and more scheduled changes land December 31. A "no" from your plan last year is not necessarily a "no" today. On eligible commercial plans, a savings card can bring the copay to $25 a month. The three questions to ask your plan are on our denial guide.
The Personal Access Report is $39, back within 24 hours: your 3 cheapest legitimate paths of the 21 programs we track, the traps that apply to you, and the questions to ask your insurer, word for word. Whatever you and your clinician decide, decide it with the real numbers on the table.
Get my report, $39 Or take the 90-second quiz firstThat is between you and your prescriber, and this page takes no position on it. Our only claim: the decision should be made against the real price, not the most expensive door's price. Sometimes the real number changes the math. Sometimes it doesn't.
Across the 11 programs where we can compare like for like, the median real maintenance price runs 1.75 times the advertised headline. Starter-dose banners, membership teasers, and billing lumps are designed so people compare headlines instead of bills.
DoseTruth audits the published prices of 21 GLP-1 programs every Monday, by hand, with a source link on every number. No program pays for placement, and rankings are never for sale.
DoseTruth is pricing information, not medical advice. Decisions about starting, continuing, or stopping any medication belong to you and your licensed healthcare provider. Prices are estimates from published program pages as of our last weekly audit and can change without notice. Discontinuation statistic: peer-reviewed preprint analysis of 73,895 users (medRxiv, 2024). All product names are trademarks of their respective owners. © 2026 DoseTruth, operated by KY Solutions.